Drug intelligence / Profile preview

BHV-1600

Development stage: Unknown
Lead developer: Biohaven

Overview

BHV-1600 is a Molecular Targeting Chimera (MoDE) engineered to rapidly degrade pathogenic autoantibodies to the β1-adrenergic receptor (β1AR). It is primarily being developed for peripartum cardiomyopathy (PPCM), a rare form of heart failure occurring at the end of pregnancy or postpartum. BHV-1600 aims to alleviate β1AR+ heart failure by routing pathogenic antibodies to the liver for degradation.

Targets

ADRB1 (β1)

Beyond the preview

Go deeper on BHV-1600.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BHV-1600.

Explore the full profile